MediQuest receives FDA response for Raynaud's drug
This article was originally published in Scrip
Executive Summary
The US FDA has told MediQuest Therapeutics that its NDA for its lead candidate, Vascana (MQX-503) – a potential topical therapy for Raynaud's disease, cannot be approved in its present form.